A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma

Protocol: 
AAAQ5401
Phase: 
I

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma

Are you Eligible? (Inclusion Criteria)

1) Patients must be at least 18 years or older of age.
2) Patients must have a histopathologically confirmed sarcoma of one of the following subtypes:
- Undifferentiated Pleomorphic Sarcoma
- Leiomyosarcoma
- Malignant Peripheral Nerve Sheath Tumor or Synovial Sarcoma
3)Patients must have had progression on at least one prior systemic chemotherapy for advanced, unresectable or metastatic disease.
4) No treatment with radiation therapy at least 4 weeks before the study.

Extension:
1) Patients cannot currently have any symptomatic, untreated, or uncontrolled brain metastases.
2) Patients with diabetes mellitus with inadequate control.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States